SG11202012070YA - Methods and compositions for preventing or treating tissue calcification - Google Patents
Methods and compositions for preventing or treating tissue calcificationInfo
- Publication number
- SG11202012070YA SG11202012070YA SG11202012070YA SG11202012070YA SG11202012070YA SG 11202012070Y A SG11202012070Y A SG 11202012070YA SG 11202012070Y A SG11202012070Y A SG 11202012070YA SG 11202012070Y A SG11202012070Y A SG 11202012070YA SG 11202012070Y A SG11202012070Y A SG 11202012070YA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- preventing
- methods
- treating tissue
- tissue calcification
- Prior art date
Links
- 230000002308 calcification Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862682796P | 2018-06-08 | 2018-06-08 | |
PCT/US2019/036138 WO2019237053A1 (en) | 2018-06-08 | 2019-06-07 | Methods and compositions for preventing or treating tissue calcification |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202012070YA true SG11202012070YA (en) | 2021-01-28 |
Family
ID=68765387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202012070YA SG11202012070YA (en) | 2018-06-08 | 2019-06-07 | Methods and compositions for preventing or treating tissue calcification |
Country Status (11)
Country | Link |
---|---|
US (7) | US10688064B2 (en) |
EP (1) | EP3801477A4 (en) |
JP (2) | JP2021527128A (en) |
KR (1) | KR20210018423A (en) |
CN (1) | CN113038940A (en) |
AU (1) | AU2019282420A1 (en) |
CA (1) | CA3102977A1 (en) |
IL (1) | IL279245B2 (en) |
MX (1) | MX2020013302A (en) |
SG (1) | SG11202012070YA (en) |
WO (1) | WO2019237053A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3801478A4 (en) | 2018-06-08 | 2022-02-23 | Epizon Pharma, Inc. | Methods and compositions for preventing or treating calciphylaxis |
WO2019237053A1 (en) | 2018-06-08 | 2019-12-12 | Epizon Pharma, Inc. | Methods and compositions for preventing or treating tissue calcification |
CA3111108A1 (en) | 2018-09-12 | 2020-03-19 | Epizon Pharma, Inc. | Menaquinol compositions and methods of treatment |
WO2020185092A2 (en) * | 2019-03-12 | 2020-09-17 | Kaydence Pharma As | Use of vitamin k in combination with anticoagulants |
JP2024523704A (en) * | 2021-07-05 | 2024-06-28 | ユニフェルシテイト マーストリヒト | Means and methods for treating calcium crystal deposition disease |
WO2023129413A1 (en) * | 2021-12-31 | 2023-07-06 | Ingredient Fusion, Llc | Molecular complexing method, formulation and manufacturing for enhanced nutrient delivery |
WO2024071848A1 (en) * | 2022-09-27 | 2024-04-04 | 경북대학교 산학협력단 | Screening method for therapeutic agent for vascular clacification |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050176778A1 (en) | 2001-08-03 | 2005-08-11 | Vitak Bv | Isoprenyl derivatives and their use in the title treatment and prevention of osteoporosis and cardiovascular calcification |
US20050123603A1 (en) | 2003-09-26 | 2005-06-09 | Natural Asa | Natural menaquinone 7 compositions |
SI1728507T1 (en) | 2005-06-03 | 2011-07-29 | Nattopharma Asa | Use of vitamin K for reversing calcification of blood vessels |
CA2657748C (en) * | 2006-07-14 | 2014-10-21 | Nattopharma Asa | Pharmaceutical and nutraceutical products comprising vitamin k2 |
GB0817528D0 (en) | 2008-09-24 | 2008-10-29 | Syntavit As | Process |
WO2012059942A2 (en) * | 2010-11-01 | 2012-05-10 | Viridis Biopharma Pvt. Ltd | Dynamic balancing of autonomic nervous system through vitamin mk-7 |
GB201203705D0 (en) | 2012-03-02 | 2012-04-18 | Kappa Bioscience As | Prodrugs |
CN104411348A (en) | 2012-06-18 | 2015-03-11 | 费森尤斯卡比德国有限公司 | Port cannula system for puncturing port catheters |
WO2014191466A1 (en) * | 2013-05-28 | 2014-12-04 | Nattopharma Asa | Menaquinone supplementation and vascular health |
GB201314245D0 (en) | 2013-08-08 | 2013-09-25 | Kappa Bioscience As | Provitamins |
US20180199610A1 (en) | 2015-02-20 | 2018-07-19 | Vitak B.V. | Vitamin k and capillary function |
JP2018514507A (en) | 2015-03-20 | 2018-06-07 | グノーシス ソシエタ ペル アチオニ | Solid form of menaquinol |
IT201700085412A1 (en) | 2017-07-26 | 2019-01-26 | Pharmanutra S P A | Composition for use in the prevention and treatment of cardiovascular diseases |
US10368858B1 (en) | 2018-01-25 | 2019-08-06 | Ring Orthopedics, Inc. | Suture passer |
WO2019237053A1 (en) | 2018-06-08 | 2019-12-12 | Epizon Pharma, Inc. | Methods and compositions for preventing or treating tissue calcification |
EP3801478A4 (en) | 2018-06-08 | 2022-02-23 | Epizon Pharma, Inc. | Methods and compositions for preventing or treating calciphylaxis |
-
2019
- 2019-06-07 WO PCT/US2019/036138 patent/WO2019237053A1/en unknown
- 2019-06-07 AU AU2019282420A patent/AU2019282420A1/en active Pending
- 2019-06-07 MX MX2020013302A patent/MX2020013302A/en unknown
- 2019-06-07 US US16/435,241 patent/US10688064B2/en active Active
- 2019-06-07 KR KR1020217000120A patent/KR20210018423A/en unknown
- 2019-06-07 SG SG11202012070YA patent/SG11202012070YA/en unknown
- 2019-06-07 JP JP2021518056A patent/JP2021527128A/en active Pending
- 2019-06-07 CN CN201980052695.9A patent/CN113038940A/en active Pending
- 2019-06-07 EP EP19814212.7A patent/EP3801477A4/en active Pending
- 2019-06-07 CA CA3102977A patent/CA3102977A1/en active Pending
- 2019-06-07 IL IL279245A patent/IL279245B2/en unknown
-
2020
- 2020-03-12 US US16/817,347 patent/US10874623B2/en active Active
- 2020-03-12 US US16/817,374 patent/US10744102B2/en active Active
- 2020-03-12 US US16/817,363 patent/US10744101B2/en active Active
- 2020-11-20 US US17/100,256 patent/US11033515B2/en active Active
-
2021
- 2021-05-11 US US17/317,488 patent/US11723882B2/en active Active
-
2023
- 2023-06-29 US US18/215,989 patent/US20240009144A1/en active Pending
-
2024
- 2024-03-19 JP JP2024043503A patent/JP2024073612A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL279245B2 (en) | 2024-03-01 |
JP2024073612A (en) | 2024-05-29 |
CA3102977A1 (en) | 2019-12-12 |
WO2019237053A1 (en) | 2019-12-12 |
US10874623B2 (en) | 2020-12-29 |
AU2019282420A1 (en) | 2021-01-07 |
US20190374484A1 (en) | 2019-12-12 |
US11723882B2 (en) | 2023-08-15 |
US10744101B2 (en) | 2020-08-18 |
IL279245B1 (en) | 2023-11-01 |
US20210378986A1 (en) | 2021-12-09 |
US20200222337A1 (en) | 2020-07-16 |
EP3801477A1 (en) | 2021-04-14 |
US20200206158A1 (en) | 2020-07-02 |
JP2021527128A (en) | 2021-10-11 |
EP3801477A4 (en) | 2022-02-23 |
US10688064B2 (en) | 2020-06-23 |
US20240009144A1 (en) | 2024-01-11 |
MX2020013302A (en) | 2021-05-12 |
IL279245A (en) | 2021-01-31 |
US20200206159A1 (en) | 2020-07-02 |
US10744102B2 (en) | 2020-08-18 |
US11033515B2 (en) | 2021-06-15 |
US20210093584A1 (en) | 2021-04-01 |
KR20210018423A (en) | 2021-02-17 |
CN113038940A (en) | 2021-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202006627B (en) | Methods and compositions for treating cancer | |
SG11202012070YA (en) | Methods and compositions for preventing or treating tissue calcification | |
GB2578539B (en) | Compositions and methods for preventing or treating muscle conditions | |
IL275626A (en) | Surface treatment compositions and methods | |
IL276808A (en) | Compositions and methods for cancer treatment | |
MX2019009753A (en) | Composition and methods for preventing radiation injury and promoting tissue regeneration. | |
IL269637A (en) | Compositions and methods for treating synucleinopathies | |
IL280413A (en) | Bismuth-thiol compositions and methods for treating wounds | |
SG11202012055PA (en) | Methods and compositions for preventing or treating calciphylaxis | |
ZA202101362B (en) | Compositions and methods for treating the eye | |
IL285886A (en) | Compositions and methods for treating laminopathies | |
SG11202012343TA (en) | Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration | |
EP3609525A4 (en) | Compositions and methods for treating or preventing gut permeability-related disorders | |
IL280348A (en) | Surface treatment compositions and methods | |
SG11202012435UA (en) | Compositions and methods for treating cancer | |
SG11202103033WA (en) | Compositions and methods for the treatment of presbyopia | |
ZA202101342B (en) | Compositions and methods for treating the eye | |
IL290348B1 (en) | Surface treatment compositions and methods | |
IL269550A (en) | Compositions and methods for treating synucleinopathies | |
IL272121A (en) | Composition and methods for the treatment of myopia | |
SG11202102442WA (en) | Methods and compositions for preventing and treating atherosclerosis and related diseases | |
IL285796A (en) | Methods and compositions for treating | |
GB202001422D0 (en) | Compositions and methods for preventing or treating nephrolithiasis | |
ZA202101360B (en) | Compositions and methods for treating the eye | |
ZA202101361B (en) | Compositions and methods for treating the eye |